Format

Send to

Choose Destination
Eur J Clin Microbiol Infect Dis. 2018 Dec;37(12):2397-2404. doi: 10.1007/s10096-018-3389-1. Epub 2018 Oct 3.

The association between treatment appropriateness according to EUCAST and CLSI breakpoints and mortality among patients with candidemia: a retrospective observational study.

Author information

1
Infectious Diseases Institute, Rambam Health Care Campus, 3109601, Haifa, Israel. n_ghanem@rambam.health.gov.il.
2
The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, 3525433, Haifa, Israel.
3
Internal Medicine Department B, Rambam Health Care Campus, 3109601, Haifa, Israel.
4
Microbiology Laboratory, Rambam Health Care Campus, 3109601, Haifa, Israel.
5
Internal Medicine Department D, Rambam Health Care Campus, 3109601, Haifa, Israel.
6
Infectious Diseases Institute, Rambam Health Care Campus, 3109601, Haifa, Israel.

Abstract

To evaluate the association between appropriate antifungal treatment and mortality among patients with candidemia using different breakpoint definitions. In a retrospective study, we included all adults with candidemia in a tertiary center between 2009 and 2015. We defined three versions of appropriate (covering) antifungal treatment, according to Clinical and Laboratory Standards Institute (CLSI) 2008, CLSI 2012, and European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2017 update) breakpoints. For empiric treatment, we evaluated the association with 30-day mortality. For definitive treatment, we evaluated the association with 90-day mortality among patients surviving the first week after candidemia onset. Adjusted odds ratios (OR) from a bivariate logistic regression with 95% confidence intervals are reported. We identified 302 patients with 308 separate candidemia episodes. The crude 30-day mortality was 55% (168/308). Resistance to anidulafungin increased from 3.5 to 51.6% and to fluconazole from 15.2 to 44.1%, when applying CLSI 2008 and EUCAST definitions, respectively. Appropriate empirical treatment was significantly associated with lower 30-day mortality using the CLSI 2008 definitions, adjusted OR 0.56 (0.33-0.96). The associations were similar, though not statistically significant for EUCAST, 0.58 (0.33-1.00), and CLSI 2012, OR 0.62 (0.37-1.04). Appropriate definitive treatment according to CLSI 2012 and EUCAST was independently associated with lower 90-day mortality, ORs 0.31 (0.13-0.75) and 0.44 (0.23-0.8), respectively. With CLSI 2008, the association was similar but not statistically significant, OR 0.4 (0.11-1.41), with few isolates classified as resistant. Considering the major shift in resistance prevalence when applying CLSI 2008, CLSI 2012, and EUCAST breakpoint definitions, no major differences were observed in their association with mortality.

KEYWORDS:

Antifungal; Breakpoints; CLSI; Candidemia; EUCAST; Mortality

PMID:
30284179
DOI:
10.1007/s10096-018-3389-1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center